Cargando…

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278724/ https://www.ncbi.nlm.nih.gov/pubmed/32581588 http://dx.doi.org/10.2147/CMAR.S263933

Ejemplares similares

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020)

Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis [Corrigendum]
Publicado: (2019)

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum]
Publicado: (2020)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution [Corrigendum]
Publicado: (2019)

Corrigendum to “System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”
por: Xu, Jun Hui, et al.
Publicado: (2022)

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China [Corrigendum]
Publicado: (2020)

Corrigendum to “Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma”
por: Fatima, Naz, et al.
Publicado: (2017)

Corrigendum to “The Oncogenic Role of ARG1 in Progression and Metastasis of Hepatocellular Carcinoma”
por: You, Jia, et al.
Publicado: (2019)

Corrigendum to: Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Traditional Chinese Medicine Astragalus Polysaccharide Enhanced Antitumor Effects of the Angiogenesis Inhibitor Apatinib in Pancreatic Cancer Cells on Proliferation, Invasiveness, and Apoptosis [Corrigendum]
Publicado: (2022)

Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
por: Gu, Xiaoying, et al.
Publicado: (2022)

Corrigendum to “Cell Cycle Genes Are Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma”
por: Liping, Xu, et al.
Publicado: (2020)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2023)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Delivery Of miR-375 And Doxorubicin By Lipid-Coated Hollow Mesoporous Silica Nanoparticles To Overcome Multiple Drug Resistance In Hepatocellular Carcinoma [Corrigendum]
Publicado: (2019)

Corrigendum for health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: And analysis from the Pulmonary Hypertension Association Registry
por: Minhas, J., et al.
Publicado: (2022)

Corrigendum to “Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells”
por: Huang, Suning, et al.
Publicado: (2020)

Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection [Corrigendum]
Publicado: (2021)

Downregulation of CENPK Suppresses Hepatocellular Carcinoma Malignant Progression through Regulating YAP1 [Corrigendum]
Publicado: (2022)

Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis [Corrigendum]
Publicado: (2022)

Corrigendum to: Pulmonary Hypertension in Heart Failure Patients
por: Rao, Sriram D, et al.
Publicado: (2020)

Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum]
Publicado: (2021)

miR-500a-3p is a Potential Prognostic Biomarker in Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum]
Publicado: (2020)

Corrigendum to Long Noncoding RNA PTTG3P Expression Is an Unfavorable Prognostic Marker for Patients With Hepatocellular Carcinoma
Publicado: (2020)

Corrigendum to “EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src”
por: Zhao, Ran, et al.
Publicado: (2021)

Corrigendum to Hypoxia‐induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway
Publicado: (2022)

[Corrigendum] MicroRNA‑92a contributes to tumor growth of human hepatocellular carcinoma by targeting FBXW7
por: Yang, Wei, et al.
Publicado: (2023)

Corrigendum to “Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients”
Publicado: (2020)

Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo [Corrigendum]
Publicado: (2020)

Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”
por: Qian, Lei, et al.
Publicado: (2022)

Corrigendum to “Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway”
por: Gao, Qingzhu, et al.
Publicado: (2023)

Corrigendum to “Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma”
por: Luo, Qizhan, et al.
Publicado: (2021)

Corrigendum to “ECG Markers of Hemodynamic Improvement in Patients with Pulmonary Hypertension”
por: Waligóra, Marcin, et al.
Publicado: (2018)

The Drug Efficacy and Adverse Reactions in a Mouse Model of Oral Squamous Cell Carcinoma Treated with Oxaliplatin at Different Time Points During a Day [Corrigendum]
Publicado: (2020)

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6jca644b0l4np3726n5h8i1pem